{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T22:18:07Z","timestamp":1768861087567,"version":"3.49.0"},"reference-count":25,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Overweight and obesity is defined as a Body Mass Index (BMI) of 25.0\u201329.9 kg\/m2 and \u226530.0 kg\/m2. The prognostic significance of obesity in metastatic prostate cancer is still unclear, especially between the castration-sensitive (CSPC) and castration-resistant (CRPC) disease states. New evidence suggests that obese patients who get androgen receptor\u2013targeted therapies may have an unexpected survival advantage. This study examined the correlation between body mass index (BMI) and survival outcomes in patients administered androgen receptor pathway inhibitors. Materials and Methods: A retrospective analysis was conducted on a cohort of 167 patients with metastatic prostate cancer treated between 2015 and 2024. BMI was analyzed as both a continuous variable and a categorical variable, which was classified as normal weight, overweight or obese. The primary goal of this study is to compare PFS and OS among BMI groups. We employed Kaplan\u2013Meier survival analysis and Cox regression modeling to evaluate prognostic indicators. The CSPC and CRPC groups were evaluated separately. Results: PFSs for normal, overweight and obese CSPC patients were 11.3, 15.1, 19.5 months, respectively; p = 0.03 but the OS did not differ significantly between BMI groups. OS for normal, overweight and obese CRPC patients were 32.8, 47.6 and 43.4 months, respectively; p = 0.01. There was also a trend toward better PFS, but it was not statistically significant. Multivariate analysis found that obesity (BMI \u2265 30) was a separate protective factor for PFS in CSPC, while high-volume disease was a bad prognostic factor for OS in CRPC. A high Gleason score and ECOG-PS 2 were consistently associated with poor outcomes. Conclusions: Obesity has a phase-dependent prognostic influence in metastatic prostate cancer, providing a PFS advantage in CSPC and an OS benefit in CRPC. These results suggest that there may be an obesity paradox in people who are getting androgen receptor\u2013targeted therapy. Further prospective studies are required to gain a better understanding of the biological reasons for this association.<\/jats:p>","DOI":"10.3390\/medicina62010202","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:23:56Z","timestamp":1768811036000},"page":"202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paradoxical Effect of Obesity on Survival Outcomes in Prostate Cancer Patients Receiving Enzalutamide and Abiraterone"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-5596","authenticated-orcid":false,"given":"Bahattin Engin","family":"Kaya","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-7964","authenticated-orcid":false,"given":"Mehmet Zahid","family":"Ko\u00e7ak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-3108","authenticated-orcid":false,"given":"O\u011fuzhan","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-0651","authenticated-orcid":false,"given":"Talat","family":"Aykut","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1455-471X","authenticated-orcid":false,"given":"Ali Fuat","family":"G\u00fcrb\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4252-1029","authenticated-orcid":false,"given":"\u00d6mer","family":"Gen\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-5931","authenticated-orcid":false,"given":"Melek","family":"Karakurt Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-9501","authenticated-orcid":false,"given":"Murat","family":"Araz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3354","authenticated-orcid":false,"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya 42080, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,18]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2000). Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Balogh, E., Patlak, M., and Nass, S.J. (2018). Incorporating Weight Management and Physical Activity Throughout the Cancer Care Continuum: Proceedings of a Workshop, National Academies Press.","DOI":"10.17226\/24925"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11912-019-0787-1","article-title":"The impact of obesity on breast cancer diagnosis and treatment","volume":"21","author":"Lee","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrendo.2014.94","article-title":"Obesity and cancer\u2014Mechanisms underlying tumour progression and recurrence","volume":"10","author":"Park","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1038\/ncomms10230","article-title":"Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity","volume":"7","author":"Laurent","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2016.67.9712","article-title":"Obesity and cancer mechanisms: Cancer metabolism","volume":"34","author":"Hopkins","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI92035","article-title":"Inflammatory mechanisms linking obesity and metabolic disease","volume":"127","author":"Saltiel","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.breast.2020.11.014","article-title":"Impact of body mass index on overall survival in patients with metastatic breast cancer","volume":"55","author":"Saleh","year":"2021","journal-title":"Breast"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.15586\/jkcvhl.v8i2.169","article-title":"Impact of body mass index on survival of metastatic renal cancer","volume":"8","author":"Plonski","year":"2021","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40520-017-0815-7","article-title":"The reverse metabolic syndrome in the elderly: Is it a \u201ccatabolic\u201d syndrome?","volume":"30","author":"Curcio","year":"2018","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Stelmach-Mardas, M., Warcho\u0142, W., Garczyk, A., Warcho\u0142, E., Korczak, J., Litwiniuk, M., Brajer-Luftmann, B., and Mardas, M. (2024). Influence of androgen deprivation therapy on the development of sarcopenia in patients with prostate cancer: A systematic review. Nutrients, 16.","DOI":"10.20944\/preprints202401.1559.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/pcan.2016.47","article-title":"Obesity and prostate cancer-specific mortality after radical prostatectomy: Results from the SEARCH database","volume":"20","author":"Vidal","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.urology.2008.05.044","article-title":"Obesity is a significant risk factor for prostate cancer at the time of biopsy","volume":"72","author":"Freedland","year":"2008","journal-title":"Urology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.euo.2025.02.006","article-title":"Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer patients randomized to receive androgen deprivation + enzalutamide \u00b1 zoledronic acid: The BONENZA study","volume":"8","author":"Buffoni","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_16","first-page":"100256","article-title":"Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Fischer","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1002\/cam4.4205","article-title":"Combination of body mass index and albumin predicts survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials","volume":"10","author":"Pan","year":"2021","journal-title":"Cancer Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Morote, J., Aguilar, A., Planas, J., and Trilla, E. (2022). Definition of castrate resistant prostate cancer: New insights. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030689"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","unstructured":"World Health Organization (2025, November 14). Obesity. Available online: https:\/\/www.who.int\/health-topics\/obesity."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1200\/JCO.2016.70.5327","article-title":"Obesity and cancer: Insights for clinicians","volume":"34","author":"Goodwin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.25749","article-title":"Metabolic risk factors in prostate cancer","volume":"117","author":"Chu","year":"2011","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/0284186X.2021.2024881","article-title":"Letter to the editor regarding the article \u201cAre older patients with non-small cell lung cancer receiving optimal care? A population-based study\u201d","volume":"61","author":"Kocak","year":"2022","journal-title":"Acta Oncol."},{"key":"ref_25","first-page":"4151","article-title":"Decreased biochemical progression in patients with castration-resistant prostate cancer using a novel mefenamic acid anti-inflammatory therapy: A randomized controlled trial","volume":"19","year":"2020","journal-title":"Oncol. Lett."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:57:14Z","timestamp":1768813034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["medicina62010202"],"URL":"https:\/\/doi.org\/10.3390\/medicina62010202","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,18]]}}}